Relugolix for the treatment of uterine fibroids
Authors:
- 17 July 2020
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 21 (14) , 1667-1674
Abstract
Uterine fibroids (UF) are benign tumors common in premenopausal women, with strong impact on the health-care systems. For many years, surgery represented the only therapy for symptomatic fibroids. ...Keywords
Funding Information
- funded
This publication has 45 references indexed in Scilit:
- The estimated annual cost of uterine leiomyomata in the United StatesAmerican Journal of Obstetrics and Gynecology, 2012
- Ulipristal Acetate versus Placebo for Fibroid Treatment before SurgeryNew England Journal of Medicine, 2012
- Ulipristal Acetate versus Leuprolide Acetate for Uterine FibroidsNew England Journal of Medicine, 2012
- MED12, theMediator Complex Subunit 12Gene, Is Mutated at High Frequency in Uterine LeiomyomasScience, 2011
- Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implicationsHuman Reproduction Update, 2011
- Discovery of 1-{4-[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a Potent, Orally Active, Non-Peptide Antagonist of the Human Gonadotropin-Releasing Hormone ReceptorJournal of Medicinal Chemistry, 2011
- Uterine Fibroid EmbolizationNew England Journal of Medicine, 2009
- Clinical presentation of fibroidsBest Practice & Research Clinical Obstetrics & Gynaecology, 2008
- GnRH agonists vs antagonistsBest Practice & Research Clinical Obstetrics & Gynaecology, 2007
- New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonistsExpert Opinion on Investigational Drugs, 2005